Apogee Therapeutics, Inc.
APGE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2,335 | $2,538 | $2,174 | $2,500 |
| - Cash | $108 | $124 | $107 | $142 |
| + Debt | $10 | $11 | $12 | $12 |
| Enterprise Value | $2,237 | $2,424 | $2,079 | $2,370 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$65 | -$73 | -$63 | -$76 |
| % Margin | – | – | – | – |
| Net Income | -$65 | -$66 | -$55 | -$67 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.11 | -1.13 | -0.95 | -1.22 |
| % Growth | 1.8% | -18.9% | 22.1% | – |
| Operating Cash Flow | -$54 | -$62 | -$48 | -$68 |
| Capital Expenditures | $0 | -$1 | -$4 | $0 |
| Free Cash Flow | -$54 | -$63 | -$53 | -$68 |